Leadership & Pay ·
Anavex Life Sciences Corp. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled…
AVXLAnavex Life Sciences Corp.
Anavex Life Sciences Corp. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled for September 24, 2026, and mailed an open letter urging stockholders to vote 'FOR' all six director nominees on the white universal proxy card. The filing highlights a contested board election against activist investor Patrick Adams through PVG Asset Management Corporation, which holds only 0.35% of shares but nominated a slate lacking FDA regulatory or drug development expertise. Anavex’s Board is refreshing its membership by nominating two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, while appointing Dr. Terrie Kellmeyer as interim CEO following the former CEO's termination in April 2026. The company emphasized its strategy to advance oral blarcamesine across three CNS indications—early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome—and prioritized FDA engagement to establish a regulatory path forward. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases.